Clinical Trials Browser

Recurrence × pembrolizumab × 1 year × Clear all

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT06984328 2026-03-03

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Phase 2 Active not recruiting

1 enrolled

Dermatologic

Melanoma, Recurrence

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT05537740 2026-02-23

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

129 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT04421560 2026-02-20

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Phase 1/2 Recruiting

37 enrolled

Neoplasms, Recurrence

NCT03445858 2026-02-18

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

Phase EARLY_PHASE1 Completed

22 enrolled

Lymphoid

Lymphoma, Neoplasms, Recurrence

NCT04534205 2026-02-12

AHEAD-MERIT

Phase 2/3 Recruiting

350 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasm Metastasis, Recurrence

NCT06052839 2026-02-09

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Phase 2 Recruiting

15 enrolled

Recurrence

NCT05533697 2026-02-06

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03082534 2026-01-28

Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase 2 Completed

78 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Neoplasm Metastasis, Oropharyngeal Neoplasms, Recurrence

NCT03618550 2025-12-02